DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 208 filers reported holding DENALI THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is 0.82 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $1,004,149 | +13.2% | 43,245 | 0.0% | 0.01% | +25.0% |
| Q1 2024 | $887,387 | -88.1% | 43,245 | -87.6% | 0.00% | -90.7% |
| Q4 2023 | $7,472,436 | +103929.5% | 348,203 | 0.0% | 0.04% | -8.5% |
| Q3 2023 | $7,183 | -30.1% | 348,203 | 0.0% | 0.05% | -29.9% |
| Q2 2023 | $10,275 | +45.3% | 348,203 | +13.4% | 0.07% | +36.7% |
| Q1 2023 | $7,073 | -17.7% | 306,970 | -0.7% | 0.05% | -24.6% |
| Q4 2022 | $8,596 | -99.9% | 309,092 | +6.1% | 0.06% | -5.8% |
| Q3 2022 | $8,940,000 | +42.7% | 291,308 | +36.9% | 0.07% | +50.0% |
| Q2 2022 | $6,263,000 | +40.6% | 212,823 | +53.7% | 0.05% | +76.9% |
| Q1 2022 | $4,456,000 | -28.6% | 138,499 | -0.0% | 0.03% | -18.8% |
| Q4 2021 | $6,242,000 | -6.3% | 138,563 | +4.9% | 0.03% | -13.5% |
| Q3 2021 | $6,662,000 | +185.2% | 132,054 | +343.4% | 0.04% | +164.3% |
| Q2 2021 | $2,336,000 | +56.8% | 29,785 | +14.1% | 0.01% | +40.0% |
| Q1 2021 | $1,490,000 | -31.8% | 26,100 | 0.0% | 0.01% | -33.3% |
| Q4 2020 | $2,186,000 | – | 26,100 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 19,462,500 | $404,042,000 | 54.41% |
| Bratton Capital Management, L.P. | 953,035 | $19,785,000 | 29.05% |
| Flagship Pioneering Inc. | 8,005,747 | $166,199,000 | 7.19% |
| Casdin Capital, LLC | 400,000 | $8,304,000,000 | 0.78% |
| Temasek Holdings (Private) Ltd | 4,410,457 | $91,561,000 | 0.65% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 22,595 | $469,000 | 0.37% |
| MARK ASSET MANAGEMENT LP | 70,532 | $1,464,000 | 0.34% |
| Artal Group S.A. | 400,000 | $8,304,000 | 0.34% |
| PIER 88 INVESTMENT PARTNERS LLC | 27,650 | $574,000 | 0.24% |
| WASATCH ADVISORS LP | 996,147 | $20,680,000 | 0.20% |